Pharming Group (OTCMKTS:PHGUF) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Pharming Group (OTCMKTS:PHGUF) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01, Zacks reports. Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.

Pharming Group Price Performance

Shares of PHGUF stock remained flat at $0.95 on Tuesday. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $640.54 million, a PE ratio of 79.54 and a beta of 0.42. The firm’s 50-day moving average is $1.07 and its 200-day moving average is $1.39. Pharming Group has a twelve month low of $0.93 and a twelve month high of $2.17.

Pharming Group Company Profile

Pharming Group N.V. is a commercial-stage biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with limited treatment options, with a focus on therapies that address unmet medical needs.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially severe swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency and immune dysregulation disorder.

Founded in 1988, Pharming has developed a commercial presence in the United States and Europe and works with regional partners and distributors in selected international markets.